2022 American Transplant Congress
Sodium-Glucose Cotransporter 2 Inhibitors to Treat Diabetes Mellitus After Kidney Transplant
*Purpose: This study describes experience prescribing sodium-glucose cotransport 2 inhibitors (SGLT2i) after kidney transplant to evaluate safety and effectiveness.*Methods: This is a retrospective, institutional review…2022 American Transplant Congress
Assessment of Insulin Utilization for Early Post-Transplant Glycemic Control in Liver Transplant
*Purpose: Transient hyperglycemia after liver transplant (LT) is common due to the use of high-dose steroids at the time of transplant, but some patients may…2022 American Transplant Congress
Safety and Efficacy of SGLT-2 Inhibitors in Solid Organ Transplant Recipients
Pharmacy, Tampa General Hospital, Tampa, FL
*Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have been shown to improve glycemic control, blood pressure, cardiovascular mortality, and preserve kidney function in the general population.…2022 American Transplant Congress
Diabetes Mellitus and Blood Glucose Variability Increases the 30-day Readmission Rate After Kidney Transplantation
*Purpose: The 30-day readmission rate is a surrogate metric of quality of care and mortality after kidney transplantation. Diabetes and observations of glucose variability during…2022 American Transplant Congress
Cardiovascular Outcomes of Kidney Transplant Recipients Receiving Belatacept Compared to a Matched Tacrolimus
*Purpose: Tacrolimus (TAC), a calcineurin inhibitor (CNI), is the backbone of maintenance immunosuppression in kidney transplant recipients (KTR) but has been associated with cardiovascular (CV)…2022 American Transplant Congress
Glucose Variability in Kidney Transplantation: Pre-Transplant and Post-Transplant Continuous Glucose Monitoring
*Purpose: Continuous glucose monitoring (CGM) provides a 24-hour view of glucose values and information on glycemic variability and additional indices such as the glucose management…2022 American Transplant Congress
Epidemiology of Post Transplant Diabetes Mellitus
Renal Medicine Department, The Royal Hospital, Bausher, Oman
*Purpose: Diabetes mellitus (DM) is a common non-communicable disease and have serious metabolic complications that contribute to death, major cardiovascular events, organs failure, and increased…2022 American Transplant Congress
Sodium-Glucose Co-Transporter 2 Inhibitors; Short-Term Outcome in Diabetic Kidney Transplant Recipients
*Purpose: The idea of using SGLT2i in kidney transplant recipients (KTR) is a legitimate one after the recent encouraging data for their use in other…2022 American Transplant Congress
Outcomes of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients
*Purpose: The impact of the new glucose lowering therapies, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP-1RA), on managing patients with type…2022 American Transplant Congress
Safety and Efficacy of GLP-1 Agonists in Solid Organ Transplant Recipients
Pharmacy, Tampa General Hospital, Tampa, FL
*Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have been shown to improve glycemic control, obesity, and cardiovascular disease in the general population. The safety and…
- 1
- 2
- 3
- …
- 7
- Next Page »